Unknown PHASE2 INTERVENTIONAL 2-arm NCT01845259

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? (GREAT)

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial

Sponsor: Psychiatric Centre Rigshospitalet

Conditions Impaired Glucose Tolerance Associated With Drugs

Interventions Liraglutide Liraglutide Placebo

Updated 6 times since 2017 Last updated: May 4, 2016 Started: Apr 30, 2013 Primary completion: Mar 31, 2016 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Impaired Glucose Tolerance Associated With Drugs, this trial is ongoing. The trial is conducted by Psychiatric Centre Rigshospitalet and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Psychiatric Centre Rigshospitalet
University Hospital, Gentofte, Copenhagen
University of Cambridge

Data source: Psychiatric Centre Rigshospitalet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark